uric acid has been researched along with Placental Insufficiency in 5 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
Placental Insufficiency: Failure of the PLACENTA to deliver an adequate supply of nutrients and OXYGEN to the FETUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this study, we attempted to assess whether uric acid could be used as a secondary marker in estimating the pregnancy risk associated with LBW." | 8.12 | Birth Weight < 3rd Percentile Prediction Using Additional Biochemical Markers-The Uric Acid Level and Angiogenesis Markers (sFlt-1, PlGF)-An Exploratory Study. ( Bednarek-Jędrzejek, M; Cymbaluk-Płoska, A; Czuba, B; Dzidek, S; Góra, T; Kwiatkowska, E; Kwiatkowski, S; Torbé, A; Tousty, P, 2022) |
| "Hyperhomocysteinemia is a risk factor in obstetrical complications such as pre-eclampsia, 'hemolysis, elevated liver enzymes, low platelet' (HELLP)-syndrome and placental insufficiency." | 7.72 | Alteration of homocysteine catabolism in pre-eclampsia, HELLP syndrome and placental insufficiency. ( Geisel, J; Herrmann, W; Hübner, U; Koch, I; Obeid, R; Retzke, U, 2004) |
| "Medical records of patients with preeclampsia and patients with PIH who delivered at term between January 2003 and December 2004 were reviewed." | 5.35 | Retinopathy in preeclampsia: association with birth weight and uric acid level. ( Gupta, A; Kaliaperumal, S; Rao, VA; Setia, S; Suchi, ST, 2008) |
| " In this study, we attempted to assess whether uric acid could be used as a secondary marker in estimating the pregnancy risk associated with LBW." | 4.12 | Birth Weight < 3rd Percentile Prediction Using Additional Biochemical Markers-The Uric Acid Level and Angiogenesis Markers (sFlt-1, PlGF)-An Exploratory Study. ( Bednarek-Jędrzejek, M; Cymbaluk-Płoska, A; Czuba, B; Dzidek, S; Góra, T; Kwiatkowska, E; Kwiatkowski, S; Torbé, A; Tousty, P, 2022) |
| "Hyperhomocysteinemia is a risk factor in obstetrical complications such as pre-eclampsia, 'hemolysis, elevated liver enzymes, low platelet' (HELLP)-syndrome and placental insufficiency." | 3.72 | Alteration of homocysteine catabolism in pre-eclampsia, HELLP syndrome and placental insufficiency. ( Geisel, J; Herrmann, W; Hübner, U; Koch, I; Obeid, R; Retzke, U, 2004) |
| "Medical records of patients with preeclampsia and patients with PIH who delivered at term between January 2003 and December 2004 were reviewed." | 1.35 | Retinopathy in preeclampsia: association with birth weight and uric acid level. ( Gupta, A; Kaliaperumal, S; Rao, VA; Setia, S; Suchi, ST, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bednarek-Jędrzejek, M | 3 |
| Dzidek, S | 3 |
| Tousty, P | 3 |
| Kwiatkowska, E | 3 |
| Cymbaluk-Płoska, A | 3 |
| Góra, T | 3 |
| Czuba, B | 3 |
| Torbé, A | 3 |
| Kwiatkowski, S | 3 |
| Asghar, ZA | 1 |
| Thompson, A | 1 |
| Chi, M | 1 |
| Cusumano, A | 1 |
| Scheaffer, S | 1 |
| Al-Hammadi, N | 1 |
| Saben, JL | 1 |
| Moley, KH | 1 |
| Gupta, A | 1 |
| Kaliaperumal, S | 1 |
| Setia, S | 1 |
| Suchi, ST | 1 |
| Rao, VA | 1 |
| Herrmann, W | 1 |
| Hübner, U | 1 |
| Koch, I | 1 |
| Obeid, R | 1 |
| Retzke, U | 1 |
| Geisel, J | 1 |
| Riedel, H | 1 |
5 other studies available for uric acid and Placental Insufficiency
| Article | Year |
|---|---|
Birth Weight < 3rd Percentile Prediction Using Additional Biochemical Markers-The Uric Acid Level and Angiogenesis Markers (sFlt-1, PlGF)-An Exploratory Study.
Topics: Biomarkers; Birth Weight; Female; Fetal Growth Retardation; Humans; Infant, Newborn; Placenta; Place | 2022 |
Birth Weight < 3rd Percentile Prediction Using Additional Biochemical Markers-The Uric Acid Level and Angiogenesis Markers (sFlt-1, PlGF)-An Exploratory Study.
Topics: Biomarkers; Birth Weight; Female; Fetal Growth Retardation; Humans; Infant, Newborn; Placenta; Place | 2022 |
Birth Weight < 3rd Percentile Prediction Using Additional Biochemical Markers-The Uric Acid Level and Angiogenesis Markers (sFlt-1, PlGF)-An Exploratory Study.
Topics: Biomarkers; Birth Weight; Female; Fetal Growth Retardation; Humans; Infant, Newborn; Placenta; Place | 2022 |
Birth Weight < 3rd Percentile Prediction Using Additional Biochemical Markers-The Uric Acid Level and Angiogenesis Markers (sFlt-1, PlGF)-An Exploratory Study.
Topics: Biomarkers; Birth Weight; Female; Fetal Growth Retardation; Humans; Infant, Newborn; Placenta; Place | 2022 |
Birth Weight < 3rd Percentile Prediction Using Additional Biochemical Markers-The Uric Acid Level and Angiogenesis Markers (sFlt-1, PlGF)-An Exploratory Study.
Topics: Biomarkers; Birth Weight; Female; Fetal Growth Retardation; Humans; Infant, Newborn; Placenta; Place | 2022 |
Birth Weight < 3rd Percentile Prediction Using Additional Biochemical Markers-The Uric Acid Level and Angiogenesis Markers (sFlt-1, PlGF)-An Exploratory Study.
Topics: Biomarkers; Birth Weight; Female; Fetal Growth Retardation; Humans; Infant, Newborn; Placenta; Place | 2022 |
Birth Weight < 3rd Percentile Prediction Using Additional Biochemical Markers-The Uric Acid Level and Angiogenesis Markers (sFlt-1, PlGF)-An Exploratory Study.
Topics: Biomarkers; Birth Weight; Female; Fetal Growth Retardation; Humans; Infant, Newborn; Placenta; Place | 2022 |
Birth Weight < 3rd Percentile Prediction Using Additional Biochemical Markers-The Uric Acid Level and Angiogenesis Markers (sFlt-1, PlGF)-An Exploratory Study.
Topics: Biomarkers; Birth Weight; Female; Fetal Growth Retardation; Humans; Infant, Newborn; Placenta; Place | 2022 |
Birth Weight < 3rd Percentile Prediction Using Additional Biochemical Markers-The Uric Acid Level and Angiogenesis Markers (sFlt-1, PlGF)-An Exploratory Study.
Topics: Biomarkers; Birth Weight; Female; Fetal Growth Retardation; Humans; Infant, Newborn; Placenta; Place | 2022 |
Maternal fructose drives placental uric acid production leading to adverse fetal outcomes.
Topics: Allopurinol; AMP Deaminase; Animals; Disease Models, Animal; Female; Fetal Growth Retardation; Fruct | 2016 |
Retinopathy in preeclampsia: association with birth weight and uric acid level.
Topics: Adolescent; Adult; Birth Weight; Blood Pressure; Female; Fetal Growth Retardation; Humans; Infant, N | 2008 |
Alteration of homocysteine catabolism in pre-eclampsia, HELLP syndrome and placental insufficiency.
Topics: Cystathionine; Cystatin C; Cystatins; Female; Folic Acid; HELLP Syndrome; Homocysteine; Humans; Hype | 2004 |
[Significance of uric acid concentration in the serum for the early recognition of the risk of EPH gestosis].
Topics: Eclampsia; Female; Humans; Hypertension; Placental Insufficiency; Pre-Eclampsia; Pregnancy; Uric Aci | 1981 |